RxDoctor Payments Data

Victoria Doan

Family · Sewickley, PANPI 1821876087

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 31 payments — averaging $34.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$361
  • AbbVie$123
  • Vertex$122
  • Pfizer$91
  • Kiniksa Pharmaceuticals International, PLC$50
  • Sanofi-aventis U.S. LLC$46
  • plus $288 from 11 others

What the payments were for

  • Food & beverage$1,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,082 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,233
Medicare patients
23
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$32,272
Praluent PenAlirocumab20$10,344
FarxigaDapagliflozin Propanediol13$7,961
Metoprolol Succinate43$961
Olmesartan Medoxomil27$734
Nebivolol Hcl18$648
Ezetimibe15$567
Amlodipine Besylate58$553
Rosuvastatin Calcium40$480
Atorvastatin Calcium37$389
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$265
Simvastatin16$230
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$199
Losartan Potassium20$190
Oxycodone Hcl14$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$32,27221 claims
AstraZenecaFarxiga$19$7,96113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Sewickley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →